| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a8a496e95f9689980ab750bd441ea508
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1c89ce4d9ac03f9acd8ddede1162f94d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_534523571cdc90350c6a93f306a0839c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d2ac943aed92ecb662fd24c8c61ec673 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-62 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-62 |
| filingDate |
2012-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1742104c25b6763728d674470d2e4c00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7dbb1beda9df3d05fadaef52f7b36eef
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f3d4168bcbf84b9e8dbbf8d5f06eff90 |
| publicationDate |
2014-08-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2014235537-A1 |
| titleOfInvention |
N-glycosylated insulin analogues |
| abstract |
Compositions and formulations comprising N-glycosylated insulin analogues are described. In particular embodiments, the glycosylated insulin analogues are produced in vivo and comprise one or more the N-linked N-glycans selected from high mannose or fucosylated or non-fucosylated hybrid, paucimannose, or complex N-glycans. In other embodiments, the N-glycan comprising the high mannose or fucosylated or non-fucosylated hybrid, paucimannose, or complex N-glycan is attached to the insulin analogue in vitro. Examples of N-glycans include but are not limited to a molecule having a structure selected from N-glycans in the group consisting of Man( 1 — 9 )GlcNAc 2 ; or selected from N-glycans in the group consisting of GlcNAc (1 — 4) Man 3 GlcNAc 2 ; or selected from N-glycans in the group consisting of Gal(j. 4)GlcNAc (1 — 4) Man 3 GlcNAe 2 ; or selected from N-glycans in the group consisting of NANA({umlaut over (ι)}_4)Gal (1 — 4) GlcN Ac (1 — 4) Man 3 GlcN Ac 2 — |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-2575756-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10822386-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11359001-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10626430-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10724013-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018187147-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10562951-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016144658-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10513724-B2 |
| priorityDate |
2011-08-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |